Background In recent years, the development of BMSCs-derived exosomes (EXO) for the
treatment of osteosarcoma (OS) is a safe and promising modality for OS treatment, which …

Chimeric antigen receptor (CAR)‑T cell therapy is an innovative approach to immune cell
therapy that works by modifying the T cells of a patient to express the CAR protein on their …

Osteosarcoma, a malignant bone tumor predominantly affecting children and adolescents,
presents significant therapeutic challenges, particularly in metastatic or recurrent cases …

Osteosarcoma (OS) is one of the most common malignant tumors in children and young
adults. As chemotherapy and other therapies are limited by low therapeutic efficiency …

Chimeric antigen receptor (CAR‐T) cell therapy is a newly developed immunotherapy
strategy and has achieved satisfactory outcomes in the treatment of hematological …

While immunotherapy is typically reserved for cancer patients with a high mutational burden,
neoantigens produced from post-transcriptional regulation provide a possible untapped …

Lung squamous cell carcinoma (LUSC) is one of the subtypes of lung cancer (LC) that
contributes to approximately 25%–30% of its prevalence. Cancer‐associated fibroblasts …

The formation of metastases during cancer is now considered to be induced by migrating
metastatic stem cells (MetSCs) in preexisting niches or niches induced by MetSCs or tumor …

Osteosarcoma (OS), a malignant tumor of the bone, is one of the most common forms of
cancer among adolescence, presenting in more than 5 per 1 million children under 15 years …

Osteosarcoma (OSA) is the most common cancer of the bone and third most common cancer
diagnosed in children and adolescent. The five-year survival rate for OSA patients …